Artepharm Co.’s leading products include the artemisinin-based combinations: the Artequick® tablet, Artequick® granules and Artemisinin raw products.
Artequick has numerous outstanding advantages, both in efficacy, course of treatment, toxicity, and convenience in usage and diversity in dosage forms. Compared to similar products, Artequick is very low-cost, has low toxicity, and is easy-to-administer with a short course of six pills. There is also an easy-to-administer children’s granular formula. The most significant advantage is the low product cost as the majority of malaria patients are typically poor.
Artepharm Co.’s principal technical service is FEMSE (Fast Elimination of Malaria at Source Eradication) technology, which has achieved superior results in hyperendemic malaria regions in Southeast Asia and Africa and has captured the attention of the international community.
Currently Artepharm Co.’s products – Artequick and the FEMSE method have the potential to become the technology leader providing the newest method of curing and controlling malaria for the highly endemic areas where it has been deployed. However, Artequick is new to the market and faces considerable competition from less-effective and more expensive incumbent products. Artepharm Co.’s objective is to quickly increase market share globally by investing in the distribution and deployment of their products.
To accomplish this, Artepharm Global Corp. plans to invest significant funds for the following purposes: